Elanco to Participate in Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 22 2024
0mins
Source: PRnewswire
Elanco Animal Health Inc's stock fell 5.01% as it crossed below the 5-day SMA amid a broader market decline.
The company will participate in the Stifel 2026 Jaws & Paws Conference on May 27, where CEO Jeff Simmons and CFO Bob VanHimbergen will discuss the company's leadership in animal health. Additionally, Simmons will present at the William Blair 46th Annual Growth Stock Conference on June 2, outlining Elanco's strategic direction and market outlook, which is expected to draw significant investor interest.
These upcoming conferences may provide insights into Elanco's future performance and strategic initiatives, potentially influencing investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.710
Low
22.00
Averages
25.50
High
30.00
Current: 24.710
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lululemon Shares Drop 10% Amid Outlook Downgrade
- Lululemon Stock Decline: Shares of Lululemon fell 10% before the market opened due to lackluster product launches and negative media coverage, which directly impacted investor confidence and led the company to lower its full-year outlook.
- Job Market Data: Economists expect May's nonfarm payrolls to increase by 80,000, a slowdown from the average of 150,000 seen in the previous two months; however, stronger-than-expected private payrolls and job openings could influence market sentiment positively.
- Quantum Computing IPO: Quantinuum's debut on Nasdaq concluded with a market value of $15.7 billion, and while the market reaction was muted, the CEO emphasized the growing need for quantum computing resources, indicating potential future demand in various sectors.
- Biotech Stocks Surge: Following the detection of the New World screwworm in Texas, biotech companies Zoetis and Elanco Animal Health saw their stocks rise in yesterday's session, reflecting increased market interest and demand for animal health products.
See More
Lululemon Shares Drop 10% Amid Outlook Downgrade
- Lululemon Stock Decline: Shares of Lululemon fell 10% before the market opened due to lackluster product launches and negative media attention, leading the company to lower its full-year outlook, indicating market concerns about its future growth prospects.
- Job Market Data: Economists expect May's nonfarm payrolls to grow by 80,000, a slowdown from the average of 150,000 seen in the previous two months, although earlier data on private payrolls and job openings exceeded expectations, suggesting potential economic recovery.
- Quantum Computing IPO: Quantinuum ended its Nasdaq debut with a market value of $15.7 billion, and while quantum computing adoption is still in its early stages, its clientele spans pharmaceuticals, finance, and government sectors, indicating a broad application potential.
- Biotech Stocks Surge: Following the detection of a flesh-eating screwworm in Texas, biotech firms Zoetis and Elanco Animal Health saw their stock prices rise in yesterday's session, reflecting increased market demand for related biocontrol measures.
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Elanco Responds to New World Screwworm Threat in U.S.
- Emerging Threat: The first confirmed case of New World screwworm in Texas poses unprecedented challenges for veterinarians, livestock producers, and pet owners, impacting animal health and producer livelihoods significantly.
- Treatment Options Offered: Elanco has introduced various treatment and prevention options, including FDA Emergency Use Authorized products like Credelio and Negasunt Powder, aimed at combating New World screwworm infestations and ensuring animal health.
- Industry Collaboration: Elanco is working alongside the U.S. animal health industry to continuously evolve management practices and implement prevention and treatment protocols to address the threat posed by New World screwworm effectively.
- Leveraging Historical Experience: With over 70 years of experience in animal health, Elanco demonstrates its leadership in the field by utilizing its global expertise to mitigate, prevent, and treat New World screwworm, reaffirming its commitment to customers.
See More
First Confirmed Case of New World Screwworm in U.S. Livestock
- Emerging Threat: The New World screwworm has been confirmed in U.S. livestock in Texas, marking its return after over 50 years of eradication, posing significant risks to animal health and producer livelihoods.
- Treatment Options Offered: Elanco Animal Health is providing a range of treatment options, including medications for dogs and cats to combat New World screwworm infestations, aimed at assisting veterinarians and livestock producers in addressing this new threat.
- Regulatory Support: Elanco expresses gratitude to the FDA, EPA, and USDA for their efforts in preparing for this challenge, ensuring that customers receive innovation and scientific expertise to combat the New World screwworm threat.
- Emergency Use Authorization: The FDA has granted emergency use authorization for Elanco's products like Credelio and Negasunt, allowing their use in animals infested with New World screwworm, reflecting a strong commitment to animal health.
See More
Pet Health Spending Continues to Rise
- Consumer Behavior Shift: Elanco's latest survey reveals that 88% of pet owners prioritize their pets' happiness and health equally with their own, indicating that pet health spending has become an emotional investment, driving sustained growth in the industry.
- Growth Potential: The animal health industry is projected to grow from $42 billion in 2025 to $60 billion over the next decade, with an average annual growth rate of about 5%, reflecting deep consumer commitment to pets and surging demand for animal protein.
- Demand for Innovative Solutions: Elanco plans to offer a diverse range of innovative products to meet pet owners' high expectations for pet health, further solidifying its leadership position in the rapidly growing pet health market.
- Market Resilience: Research from Elanco indicates that the animal health industry has shown continuous growth over the past 20 years, with a 7% expansion rate in 2025, demonstrating the sector's resilience and stability amid economic fluctuations.
See More
Lululemon Shares Drop 10% Amid Outlook Downgrade
- Lululemon Stock Decline: Shares of Lululemon fell 10% before the market opened due to lackluster product launches and negative media coverage, which directly impacted investor confidence and led the company to lower its full-year outlook.
- Job Market Data: Economists expect May's nonfarm payrolls to increase by 80,000, a slowdown from the average of 150,000 seen in the previous two months; however, stronger-than-expected private payrolls and job openings could influence market sentiment positively.
- Quantum Computing IPO: Quantinuum's debut on Nasdaq concluded with a market value of $15.7 billion, and while the market reaction was muted, the CEO emphasized the growing need for quantum computing resources, indicating potential future demand in various sectors.
- Biotech Stocks Surge: Following the detection of the New World screwworm in Texas, biotech companies Zoetis and Elanco Animal Health saw their stocks rise in yesterday's session, reflecting increased market interest and demand for animal health products.
See More
Lululemon Shares Drop 10% Amid Outlook Downgrade
- Lululemon Stock Decline: Shares of Lululemon fell 10% before the market opened due to lackluster product launches and negative media attention, leading the company to lower its full-year outlook, indicating market concerns about its future growth prospects.
- Job Market Data: Economists expect May's nonfarm payrolls to grow by 80,000, a slowdown from the average of 150,000 seen in the previous two months, although earlier data on private payrolls and job openings exceeded expectations, suggesting potential economic recovery.
- Quantum Computing IPO: Quantinuum ended its Nasdaq debut with a market value of $15.7 billion, and while quantum computing adoption is still in its early stages, its clientele spans pharmaceuticals, finance, and government sectors, indicating a broad application potential.
- Biotech Stocks Surge: Following the detection of a flesh-eating screwworm in Texas, biotech firms Zoetis and Elanco Animal Health saw their stock prices rise in yesterday's session, reflecting increased market demand for related biocontrol measures.
See More
Screwworm Fears Spark Market Activity for Zoetis and Elanco
- Market Reaction: The discovery of New World screwworm in Texas has led to shares of Zoetis and Elanco Animal Health rising nearly 4% and 2% respectively on Thursday, indicating strong market interest in animal health products.
- Surge in Options Trading: Options volume for Zoetis surged to almost 20 times the daily average, with nearly 12,000 contracts traded, including the purchase of 4,200 call options, reflecting investor optimism about the company's future performance.
- FDA Support: Zoetis received conditional FDA approval last year for an injectable product that treats and prevents reinfestation of the screwworm, and last month the FDA issued emergency use authorization, bolstering market confidence in the product.
- Beef Supply Risks: While cattle futures are up over 1%, the potential spread of the screwworm could strain beef supply, leading to market volatility among American consumers who favor fast food, highlighting the economic implications of this event.
See More
Elanco Responds to New World Screwworm Threat in U.S.
- Emerging Threat: The first confirmed case of New World screwworm in Texas poses unprecedented challenges for veterinarians, livestock producers, and pet owners, impacting animal health and producer livelihoods significantly.
- Treatment Options Offered: Elanco has introduced various treatment and prevention options, including FDA Emergency Use Authorized products like Credelio and Negasunt Powder, aimed at combating New World screwworm infestations and ensuring animal health.
- Industry Collaboration: Elanco is working alongside the U.S. animal health industry to continuously evolve management practices and implement prevention and treatment protocols to address the threat posed by New World screwworm effectively.
- Leveraging Historical Experience: With over 70 years of experience in animal health, Elanco demonstrates its leadership in the field by utilizing its global expertise to mitigate, prevent, and treat New World screwworm, reaffirming its commitment to customers.
See More
First Confirmed Case of New World Screwworm in U.S. Livestock
- Emerging Threat: The New World screwworm has been confirmed in U.S. livestock in Texas, marking its return after over 50 years of eradication, posing significant risks to animal health and producer livelihoods.
- Treatment Options Offered: Elanco Animal Health is providing a range of treatment options, including medications for dogs and cats to combat New World screwworm infestations, aimed at assisting veterinarians and livestock producers in addressing this new threat.
- Regulatory Support: Elanco expresses gratitude to the FDA, EPA, and USDA for their efforts in preparing for this challenge, ensuring that customers receive innovation and scientific expertise to combat the New World screwworm threat.
- Emergency Use Authorization: The FDA has granted emergency use authorization for Elanco's products like Credelio and Negasunt, allowing their use in animals infested with New World screwworm, reflecting a strong commitment to animal health.
See More
Pet Health Spending Continues to Rise
- Consumer Behavior Shift: Elanco's latest survey reveals that 88% of pet owners prioritize their pets' happiness and health equally with their own, indicating that pet health spending has become an emotional investment, driving sustained growth in the industry.
- Growth Potential: The animal health industry is projected to grow from $42 billion in 2025 to $60 billion over the next decade, with an average annual growth rate of about 5%, reflecting deep consumer commitment to pets and surging demand for animal protein.
- Demand for Innovative Solutions: Elanco plans to offer a diverse range of innovative products to meet pet owners' high expectations for pet health, further solidifying its leadership position in the rapidly growing pet health market.
- Market Resilience: Research from Elanco indicates that the animal health industry has shown continuous growth over the past 20 years, with a 7% expansion rate in 2025, demonstrating the sector's resilience and stability amid economic fluctuations.
See More
